Regeneron Says FDA Approves Eylea Injection for All Diabetic Retinopathy Treatment

Date : 05/13/2019 @ 8:29PM
Source : Dow Jones News
Stock : Regeneron Pharmaceuticals Inc (REGN)
Quote : 305.645  0.205 (0.07%) @ 4:05PM

Regeneron Says FDA Approves Eylea Injection for All Diabetic Retinopathy Treatment

Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart

6 Months : From Apr 2019 to Oct 2019

Click Here for more Regeneron Pharmaceuticals Charts.

By Michael Dabaie

 

Regeneron Pharmaceuticals Inc. (REGN) said the Food and Drug Administration approved Eylea injection to treat all stages of diabetic retinopathy.

The company said Eylea improves diabetic retinopathy and prevents worsening disease that can lead to blindness. Diabetic retinopathy is the leading cause of blindness among working-aged American adults, Regeneron said.

The FDA approval of Eylea as a treatment for diabetic retinopathy was based on six-month and one-year results from Panorama, a randomized, multi-center, controlled Phase 3 trial that enrolled 402 patients.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

May 13, 2019 15:14 ET (19:14 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest REGN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.